Your browser doesn't support javascript.
loading
Single-cell genomic variation induced by mutational processes in cancer.
Funnell, Tyler; O'Flanagan, Ciara H; Williams, Marc J; McPherson, Andrew; McKinney, Steven; Kabeer, Farhia; Lee, Hakwoo; Salehi, Sohrab; Vázquez-García, Ignacio; Shi, Hongyu; Leventhal, Emily; Masud, Tehmina; Eirew, Peter; Yap, Damian; Zhang, Allen W; Lim, Jamie L P; Wang, Beixi; Brimhall, Jazmine; Biele, Justina; Ting, Jerome; Au, Vinci; Van Vliet, Michael; Liu, Yi Fei; Beatty, Sean; Lai, Daniel; Pham, Jenifer; Grewal, Diljot; Abrams, Douglas; Havasov, Eliyahu; Leung, Samantha; Bojilova, Viktoria; Moore, Richard A; Rusk, Nicole; Uhlitz, Florian; Ceglia, Nicholas; Weiner, Adam C; Zaikova, Elena; Douglas, J Maxwell; Zamarin, Dmitriy; Weigelt, Britta; Kim, Sarah H; Da Cruz Paula, Arnaud; Reis-Filho, Jorge S; Martin, Spencer D; Li, Yangguang; Xu, Hong; de Algara, Teresa Ruiz; Lee, So Ra; Llanos, Viviana Cerda; Huntsman, David G.
Afiliação
  • Funnell T; Tri-Institutional PhD Program in Computational Biology and Medicine, Weill Cornell Medicine, New York, NY, USA.
  • O'Flanagan CH; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Williams MJ; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
  • McPherson A; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. william1@mskcc.org.
  • McKinney S; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Kabeer F; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Lee H; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Salehi S; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Vázquez-García I; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Shi H; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Leventhal E; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Masud T; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Eirew P; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Yap D; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Zhang AW; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Lim JLP; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Wang B; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Brimhall J; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Biele J; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Ting J; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Au V; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Van Vliet M; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Liu YF; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Beatty S; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Lai D; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Pham J; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Grewal D; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Abrams D; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Havasov E; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Leung S; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Bojilova V; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Moore RA; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Rusk N; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Uhlitz F; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Ceglia N; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Weiner AC; Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada.
  • Zaikova E; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Douglas JM; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Zamarin D; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Weigelt B; Tri-Institutional PhD Program in Computational Biology and Medicine, Weill Cornell Medicine, New York, NY, USA.
  • Kim SH; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Da Cruz Paula A; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Reis-Filho JS; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Martin SD; GYN Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Li Y; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Xu H; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • de Algara TR; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Lee SR; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Llanos VC; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Huntsman DG; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Nature ; 612(7938): 106-115, 2022 12.
Article em En | MEDLINE | ID: mdl-36289342
How cell-to-cell copy number alterations that underpin genomic instability1 in human cancers drive genomic and phenotypic variation, and consequently the evolution of cancer2, remains understudied. Here, by applying scaled single-cell whole-genome sequencing3 to wild-type, TP53-deficient and TP53-deficient;BRCA1-deficient or TP53-deficient;BRCA2-deficient mammary epithelial cells (13,818 genomes), and to primary triple-negative breast cancer (TNBC) and high-grade serous ovarian cancer (HGSC) cells (22,057 genomes), we identify three distinct 'foreground' mutational patterns that are defined by cell-to-cell structural variation. Cell- and clone-specific high-level amplifications, parallel haplotype-specific copy number alterations and copy number segment length variation (serrate structural variations) had measurable phenotypic and evolutionary consequences. In TNBC and HGSC, clone-specific high-level amplifications in known oncogenes were highly prevalent in tumours bearing fold-back inversions, relative to tumours with homologous recombination deficiency, and were associated with increased clone-to-clone phenotypic variation. Parallel haplotype-specific alterations were also commonly observed, leading to phylogenetic evolutionary diversity and clone-specific mono-allelic expression. Serrate variants were increased in tumours with fold-back inversions and were highly correlated with increased genomic diversity of cellular populations. Together, our findings show that cell-to-cell structural variation contributes to the origins of phenotypic and evolutionary diversity in TNBC and HGSC, and provide insight into the genomic and mutational states of individual cancer cells.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Genômica / Análise de Célula Única / Neoplasias de Mama Triplo Negativas / Mutação Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Genômica / Análise de Célula Única / Neoplasias de Mama Triplo Negativas / Mutação Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article